6.20
5,199%
+6.083
After Hours:
6.43
0.23
+3.71%
Avenue Therapeutics Inc stock is currently priced at $6.20, with a 24-hour trading volume of 228.09K.
It has seen a +5,199% increased in the last 24 hours and a +4,006% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.1074 pivot point. If it approaches the $0.1644 resistance level, significant changes may occur.
Previous Close:
$0.117
Open:
$7.48
24h Volume:
228.09K
Market Cap:
$3.66M
Revenue:
-
Net Income/Loss:
$-10.38M
P/E Ratio:
-1.2389
EPS:
-5.0046
Net Cash Flow:
$-12.45M
1W Performance:
+4,669%
1M Performance:
+4,006%
6M Performance:
+1,677%
1Y Performance:
+581.32%
Avenue Therapeutics Inc Stock (ATXI) Company Profile
Name
Avenue Therapeutics Inc
Sector
Industry
Phone
781 652 4500
Address
1140 Avenue of the America, 9th Floor, New York, NY
Avenue Therapeutics Inc Stock (ATXI) Latest News
Avenue Therapeutics Announces Reverse Stock Split
GlobeNewswire Inc.
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
GlobeNewswire Inc.
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
GlobeNewswire Inc.
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
GlobeNewswire Inc.
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Benzinga
Why Fangdd Network Group Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
Benzinga
Avenue Therapeutics Inc Stock (ATXI) Financials Data
Avenue Therapeutics Inc (ATXI) Net Income 2024
ATXI net income (TTM) was -$10.38 million for the quarter ending December 31, 2023, a -192.15% decrease year-over-year.
Avenue Therapeutics Inc (ATXI) Cash Flow 2024
ATXI recorded a free cash flow (TTM) of -$12.45 million for the quarter ending December 31, 2023, a -63.92% decrease year-over-year.
Avenue Therapeutics Inc (ATXI) Earnings per Share 2024
ATXI earnings per share (TTM) was -$3.81 for the quarter ending December 31, 2023, a -36.58% decline year-over-year.
About Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.
Cap:
|
Volume (24h):